Areas of good practice
Any allergy-related medication safety concern was escalated or actioned where identified.
100%
Allergy-related prescribing discrepancy was actioned where identified.
93.8%
Priority gaps
Drug/allergen and reaction details were included in discharge communication where relevant. (target ≥ 85%)
20.8%
Documentation distinguished allergy from intolerance, side effect or adverse drug reaction where possible. (target ≥ 85%)
25%
Allergy alert or prescribing warning was present where relevant and supported by the system. (target ≥ 85%)
25%
Reason for incomplete, missing or inconsistent allergy documentation was recorded where applicable. (target ≥ 80%)
27.1%
Reaction timing, approximate date or circumstances were documented where available. (target ≥ 80%)
53.8%
Allergy status was coded or structured correctly where the EPR / prescribing system supports coding. (target ≥ 85%)
62.5%
Allergy information was consistent across clinical notes, prescribing record and discharge/transfer documentation. (target ≥ 90%)
68.8%
Drug or allergen name was documented where an allergy or suspected allergy was present. (target ≥ 90%)
69.2%
Reaction severity was documented. (target ≥ 85%)
69.2%
Allergy status was visible at the point of prescribing or administration. (target ≥ 90%)
70.8%
Allergy information was verified with an appropriate source where possible. (target ≥ 85%)
70.8%
Source of allergy information was documented. (target ≥ 85%)
70.8%
Reaction signs or symptoms were documented. (target ≥ 90%)
76.9%
Allergy status was included in discharge summary or transfer communication. (target ≥ 90%)
79.2%
Documentation was clear enough for another clinician, nurse or pharmacist to prescribe or administer medicines safely. (target ≥ 90%)
79.2%
Allergy status was documented in the prescribing or medicines administration system. (target ≥ 90%)
83.3%
No known allergy status was explicitly documented where applicable. (target ≥ 90%)
87.5%
Allergy status was reviewed during medicines reconciliation where medicines reconciliation was required. (target ≥ 90%)
87.5%
Allergy status was documented in the clinical record. (target ≥ 90%)
89.6%
User commentary
Editable interpretation for reports and governance meetings.
Governance & safety implications
Any immediate allergy, prescribing, anaphylaxis or medication safety concern identified during this audit must be escalated through local clinical, pharmacy, incident reporting and governance pathways. This tool does not replace local escalation processes.